Add to ORKGBackground: The prognostic value of discordant immunologic (CD4 cell increase) and virologic (plasma HIV RNA level decrease) responses to antiretroviral treatment is not known. Objective: To study the relation between clinical outcome of HIV-infected patients receiving highly active antiretroviral therapy (HAART) and early immunologic and virologic responses to such therapy. Design: Prospective cohort study
Objectives: To evaluate prior antiretroviral therapy experience and host characteristics as determin...
Background. Factors that determine the immunological response to highly active antiretroviral therap...
ObjectiveDespite evidence supporting antiretroviral therapy (ART) in recent HIV infection, little is...
Background: A subgroup of human immunodeficiency virus type 1 (HIV-1)–infected patients with severe ...
Abstract- Current mainstay of treatment for human immunodeficiency virus (HIV)-infected patients is ...
Limited information exists on long-term prognosis of patients with sustained virologic response to a...
Background: We examined whether the initial virological and immunological response to highly active ...
Background: The aim of present study was to investigate the Consequence of Immunologic and Virologic...
Objective: To evaluate the influence of immunological and virological markers on clinical outcome in...
BACKGROUND: Limited information exists on long-term prognosis of patients with sustained virologic r...
BACKGROUND: The efficacy of highly active antiretroviral therapy (HAART) in suppression of HIV-1 is ...
OBJECTIVE: When to start highly active antiretroviral therapy (HAART) in asymptomatic chronically HI...
Little is known about the long-term clinical outcomes for human immunodeficiency virus (HIV)-infecte...
HIV RNA monitoring is not available in most antiretroviral treatment (ART) programs in sub-Saharan A...
Background: Control of HIV replication can be observed in highly active antiretroviral therapy (HAAR...
Objectives: To evaluate prior antiretroviral therapy experience and host characteristics as determin...
Background. Factors that determine the immunological response to highly active antiretroviral therap...
ObjectiveDespite evidence supporting antiretroviral therapy (ART) in recent HIV infection, little is...
Background: A subgroup of human immunodeficiency virus type 1 (HIV-1)–infected patients with severe ...
Abstract- Current mainstay of treatment for human immunodeficiency virus (HIV)-infected patients is ...
Limited information exists on long-term prognosis of patients with sustained virologic response to a...
Background: We examined whether the initial virological and immunological response to highly active ...
Background: The aim of present study was to investigate the Consequence of Immunologic and Virologic...
Objective: To evaluate the influence of immunological and virological markers on clinical outcome in...
BACKGROUND: Limited information exists on long-term prognosis of patients with sustained virologic r...
BACKGROUND: The efficacy of highly active antiretroviral therapy (HAART) in suppression of HIV-1 is ...
OBJECTIVE: When to start highly active antiretroviral therapy (HAART) in asymptomatic chronically HI...
Little is known about the long-term clinical outcomes for human immunodeficiency virus (HIV)-infecte...
HIV RNA monitoring is not available in most antiretroviral treatment (ART) programs in sub-Saharan A...
Background: Control of HIV replication can be observed in highly active antiretroviral therapy (HAAR...
Objectives: To evaluate prior antiretroviral therapy experience and host characteristics as determin...
Background. Factors that determine the immunological response to highly active antiretroviral therap...
ObjectiveDespite evidence supporting antiretroviral therapy (ART) in recent HIV infection, little is...